STAT

3 China biotech stories to watch in 2019

In 2018, biotech in China generated relentless news. What's next for 2019?

As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here

This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Opinion: Virtual And Augmented Reality Can Save Lives By Improving Surgeons’ Training
Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing t
STAT2 min read
This Troubled Biotech Needed Cash, So It Turned To A Predatory Lender: Its Own CEO
I don’t write about Northwest Biotherapeutics much anymore because it’s not cool to punch down. However, there was a juicy nugget in the cancer biotech’s recently filed 10-Q that had to be shared. It’s another example of a biotech executive getting r
STAT7 min read
Opinion: Novartis Violated FDA’s Sacred Principle: In God We Trust, All Others Must Bring Data
My experience in more than 40 years of developing and evaluating medical products, and two years working at the FDA, has convinced me that it's essential to have a second…